Family Blood Pressure Program - HyperGEN
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To map and identify the major genetic determinants of hypertension and to study possible interactions between genetic and non-genetic factors in defined populations. HyperGEN initially consisted of a nine grant network, which in turn is part of an NHLBI initiative, the Family Blood Pressure Program (FBPP) consisting of four networks.
| Condition |
|---|
|
Cardiovascular Diseases Heart Diseases Hypertension |
| Study Type: | Observational |
| Study Design: | Observational Model: Family-Based Time Perspective: Cross-Sectional |
Tissue suitable for DNA extraction
| Enrollment: | 3604 |
| Study Start Date: | September 1995 |
| Study Completion Date: | August 2008 |
| Primary Completion Date: | August 2008 (Final data collection date for primary outcome measure) |
Show Detailed Description
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
(A) sample of hypertensive sibships with at least two members diagnosed with hypertension before the age of 60 (probands); (B) random sample of age-matched persons from the same base populations, from which normotensive controls could be drawn; (C) unmedicated, normotensive adult offspring of one of the hypertensive siblings.
Inclusion criteria for probands: Onset of hypertension by age 60 years and the presence of at least one additional hypertensive sibling who was willing to participate. Hypertension was defined according to systolic BP ≥140 or diastolic BP ≥90 in at least two different evaluations, or treatment for hypertension. Volunteers with type 1 diabetes or renal failure were excluded.
Inclusion criteria for subsequent recruits: Criteria as indicated in Study Population Description (i.e., criteria based on familial relationships, hypertension and antihypertensive medication status).
Contacts and Locations| Principal Investigator: | Donna Arnett | University of Alabama at Birmingham |
| Principal Investigator: | John Eckfeldt | University of Minnesota - Clinical and Translational Science Institute |
| Principal Investigator: | R.Curtis Ellison | Boston University |
| Principal Investigator: | Steven Hunt | University of Utah |
| Principal Investigator: | Jean-Marc Lalouel | University of Utah |
| Principal Investigator: | Cora Lewis | University of Alabama at Birmingham |
| Principal Investigator: | Kari North | University of North Carolina |
| Principal Investigator: | James Pankow | University of Minnesota - Clinical and Translational Science Institute |
| Principal Investigator: | Dabeeru Rao | Washington University School of Medicine |
More Information
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Donna K. Arnett, PhD, Professor, Chair, Professor, University of Alabama at Birmingham |
| ClinicalTrials.gov Identifier: | NCT00005267 History of Changes |
| Other Study ID Numbers: | 1151, 5R01HL055673-15 |
| Study First Received: | May 25, 2000 |
| Last Updated: | June 18, 2012 |
| Health Authority: | United States: Federal Government |
Additional relevant MeSH terms:
|
Cardiovascular Diseases Heart Diseases Hypertension Vascular Diseases |
ClinicalTrials.gov processed this record on May 23, 2013